Salmonella in poultry: improving vaccine efficacy . The central aim of this project is to increase the antigenicity of aroA mutant Salmonella Typhimurium vaccines, in particular Bioproperties’ Vaxsafe® ST. Increased antigenicity will affect the gut microbiota and stimulate a stronger host immune response improving vaccine efficacy and the duration of protection against S. Typhimurium in poultry. This will ultimately reduce bacterial loads in the farm environment, mitigate downstream contaminatio ....Salmonella in poultry: improving vaccine efficacy . The central aim of this project is to increase the antigenicity of aroA mutant Salmonella Typhimurium vaccines, in particular Bioproperties’ Vaxsafe® ST. Increased antigenicity will affect the gut microbiota and stimulate a stronger host immune response improving vaccine efficacy and the duration of protection against S. Typhimurium in poultry. This will ultimately reduce bacterial loads in the farm environment, mitigate downstream contamination of the food supply chain, and reduce the number of human salmonellosis cases.Read moreRead less
Molecular approaches to solving current and emerging problems in the epidemiology and diagnosis of Marek's disease in Australia. Marek's disease (MD) is a ubiquitous viral disease of chickens that is currently controlled in meat chickens by blanket vaccination of all chickens. However, as has happened overseas, the efficacy of the HVT vaccine being used in Australia is breaking down resulting in subclinical and clinical losses due to MD. To assist industry deal with this situation we propose to ....Molecular approaches to solving current and emerging problems in the epidemiology and diagnosis of Marek's disease in Australia. Marek's disease (MD) is a ubiquitous viral disease of chickens that is currently controlled in meat chickens by blanket vaccination of all chickens. However, as has happened overseas, the efficacy of the HVT vaccine being used in Australia is breaking down resulting in subclinical and clinical losses due to MD. To assist industry deal with this situation we propose to develop novel molecular methods for the quantification of Marek's disease viruses (MDV) in the host and the environment, to use these methods to design effective early monitoring systems for MD in broilers that predict disease and performance outcomes, and to develop an epidemiological model that will predict the spread and severity of MD as failure of vaccinal protection progresses.Read moreRead less
Development of an Attenuated Infectious Laryngotracheitis Virus Vaccine. This project will develop novel methods for identification of genes involved in virulence of the important avian pathogen Infectious Laryngotracheitis Virus and produce an attenuated, antigenically marked infectious laryngotracheitis virus vaccine strain by specific disruption and deletion of two or more genes in the virusÕs genome.
Infectious laryngotracheitis is a major disease of chickens throughout the world, but curre ....Development of an Attenuated Infectious Laryngotracheitis Virus Vaccine. This project will develop novel methods for identification of genes involved in virulence of the important avian pathogen Infectious Laryngotracheitis Virus and produce an attenuated, antigenically marked infectious laryngotracheitis virus vaccine strain by specific disruption and deletion of two or more genes in the virusÕs genome.
Infectious laryngotracheitis is a major disease of chickens throughout the world, but current vaccines retain some capacity to cause disease. The development of novel attenuated vaccines will thus enhance control of this important disease of poultry.Read moreRead less
Optimising the efficacy of mycoplasma vaccines in the field. Optimising the efficacy of mycoplasma vaccines in the field. This project intends to examine the effect of antibiotic treatment, killed vaccines and immunosuppressive viruses on the protective immunity induced by a model novel vaccine against the important poultry pathogen Mycoplasma gallisepticum. The continued circulation of pathogenic mycoplasmas in intensively managed animals is a major animal health problem. Live attenuated vaccin ....Optimising the efficacy of mycoplasma vaccines in the field. Optimising the efficacy of mycoplasma vaccines in the field. This project intends to examine the effect of antibiotic treatment, killed vaccines and immunosuppressive viruses on the protective immunity induced by a model novel vaccine against the important poultry pathogen Mycoplasma gallisepticum. The continued circulation of pathogenic mycoplasmas in intensively managed animals is a major animal health problem. Live attenuated vaccines could reduce disease, but we have limited understanding of the best conditions for their use. This project will generate data to guide both use and development of live mycoplasma vaccines. It is expected to have significant impacts on animal health, welfare and production, and public health by reducing the use of antibiotics to control mycoplasmoses.Read moreRead less
Genomic sequencing and comparative genomic analysis for animal bacterial vaccine discovery. The aim of this project is to develop vaccines for the control of swine dysentery (pigs) and intestinal spirochaetosis (pigs and chickens). These infections cause important production-limiting diseases for which no effective vaccines are available. We will use whole genomic sequencing of the two causal species of intestinal spirochaetal bacteria, with a bioinformatics-based analysis of the data to identif ....Genomic sequencing and comparative genomic analysis for animal bacterial vaccine discovery. The aim of this project is to develop vaccines for the control of swine dysentery (pigs) and intestinal spirochaetosis (pigs and chickens). These infections cause important production-limiting diseases for which no effective vaccines are available. We will use whole genomic sequencing of the two causal species of intestinal spirochaetal bacteria, with a bioinformatics-based analysis of the data to identify potential cell surface structures that will be tested as the basis of new recombinant vaccines. Outcomes will include the development of new commercial products, increased institutional capacity in veterinary vaccine discovery, and ultimately improved animal health and production in rural Australia.Read moreRead less
Development of a live vaccine for gut health in poultry. Development of a live vaccine for gut health in poultry. The project aims to develop a live vaccine against necrotic enteritis, a disease of poultry estimated to cost the global poultry industry $5-6 billion USD/annum. It builds on work that has demonstrated the efficacy of an experimental vaccine. The proven antigen, NetB, will be expressed in live delivery vehicles, including the apicomplexan parasite Eimeria and several bacteria strains ....Development of a live vaccine for gut health in poultry. Development of a live vaccine for gut health in poultry. The project aims to develop a live vaccine against necrotic enteritis, a disease of poultry estimated to cost the global poultry industry $5-6 billion USD/annum. It builds on work that has demonstrated the efficacy of an experimental vaccine. The proven antigen, NetB, will be expressed in live delivery vehicles, including the apicomplexan parasite Eimeria and several bacteria strains particularly suited to use in chickens. Comparative analysis of the different vaccine vehicles will allow evaluation of the relative advantages and disadvantage of the different vehicles for delivery of heterologous vaccine antigens, thus informing the choice of appropriate vectors for this and other vaccine applications.Read moreRead less
Reducing the health & economic burden of Campylobacter using a live vaccine. The aim of the project is to develop a vaccine to reduce Campylobacter bacteria in chickens. Campylobacters cause disease in both poultry and humans. Poultry products are the most common source of human infections. By reducing Campylobacter in poultry, the transfer to humans will be reduced. The expected outcomes arising from this work will be a reduction of the economic burden of poultry losses, in an Australian indust ....Reducing the health & economic burden of Campylobacter using a live vaccine. The aim of the project is to develop a vaccine to reduce Campylobacter bacteria in chickens. Campylobacters cause disease in both poultry and humans. Poultry products are the most common source of human infections. By reducing Campylobacter in poultry, the transfer to humans will be reduced. The expected outcomes arising from this work will be a reduction of the economic burden of poultry losses, in an Australian industry valued at $2.8 billion/year, and an improvement in food safety, thus helping to reduce the burden of foodborne illness, estimated to be $1.2 billion dollars/year. This project is, therefore, poised to benefit the Australian economy, specifically primary producers and the general public, by targeted vaccination of poultry.Read moreRead less